Abstract
Positron emission tomography (PET) is a powerful molecular imaging technique for the human body-imaging applications currently available. As altered glucose metabolism is characteristic for many malignancies, FDG-PET is mostly used in oncology for staging and therapy control. Although PET is a sensitive tool for detecting malignancy, FDG uptake is not tumor specific. It can also be seen in healthy tissue or in benign disease as inflammation or posttraumatic repair and could be mistaken for cancer. The experienced nuclear medicine physician mostly manages to differentiate malignant from non-malignant FDG uptake, but some findings may remain ambiguous. In these cases, the difficulties in differentiating physiologic variants or benign causes of FDG uptake from tumor tissue can often be overcome by combined PET and CT (PET/CT) as anatomic information is added to the metabolic data. Thus, PET/CT improves the diagnostic accuracy compared to PET alone and helps to avoid unnecessary surgery/therapy. However, PET/CT involves other sources of artifacts that may occur when using CT for attenuation correction of PET or by patient motion caused by respiration or bowel movements.
Similar content being viewed by others
References
Avril N (2004) GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 45(6):930-932
Hany TF, Gharehpapagh E, Kamel EM, Buck A, Himms-Hagen J, von Schulthess GK (2002) Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging 29(10):1393-1398
Yeung HW, Grewal RK, Gonen M, Schoder H, Larson SM (2003) Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false- positives for PET. J Nucl Med 44(11):1789-1796
Cohade C, Osman M, Pannu HK, Wahl RL (2003) Uptake in supraclavicular area fat ("USA-Fat"): description on 18F-FDG PET/CT. J Nucl Med 44(2):170-176
Himms-Hagen J (1984) Impaired thermogenesis and brown fat in obesity. Can J Surg 27(2):125
Kamel EM, Goerres GW, Burger C, von Schulthess GK, Steinert HC (2002) Recurrent laryngeal nerve palsy in patients with lung cancer: detection with PET-CT image fusion–report of six cases. Radiology 224(1):153-156
Kostakoglu L, Wong JC, Barrington SF, Cronin BF, Dynes AM, Maisey MN (1996) Speech-related visualization of laryngeal muscles with fluorine-18-FDG. J Nucl Med 37(11):1771-1773
Fujii H, Ide M, Yasuda S, Takahashi W, Shohtsu A, Kubo A (1999) Increased FDG uptake in the wall of the right atrium in people who participated in a cancer screening program with whole-body PET. Ann Nucl Med 13(1):55-59
Yasuda S, Shohtsu A, Ide M, et al (1998) Chronic thyroiditis: diffuse uptake of FDG at PET. Radiology 207(3):775-778
Cohen MS, Arslan N, Dehdashti F, et al (2001) Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery 130(6):941-946
Lerman H, Metser U, Grisaru D, Fishman A, Lievshitz G, Even-Sapir E (2004) Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med 45(2):266-271
Kosuda S, Fisher S, Kison PV, Wahl RL, Grossman HB (1997) Uptake of 2- deoxy-2-[18F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med 11(3):195-199
Maurea S, Mainolfi C, Bazzicalupo L, et al (1999) Imaging of adrenal tumors using FDG PET: comparison of benign and malignant lesions. AJR Am J Roentgenol 173(1):25-29
Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A (2001) 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 42(12):1795-1799
Lin EC, Helgans R (2002) Adrenal hyperplasia in Cushing’s syndrome demonstrated by FDG positron emission tomographic imaging. Clin Nucl Med 27(7):516-517
Shimizu A, Oriuchi N, Tsushima Y, Higuchi T, Aoki J, Endo K (2003) High [18F] 2-fluoro-2-deoxy-D-glucose (FDG) uptake of adrenocortical adenoma showing subclinical Cushing’s syndrome. Ann Nucl Med 17(5):403-406
Cook GJ, Maisey MN, Fogelman I (1999) Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. Eur J Nucl Med 26(10):1363-1378
Patel PM, Alibazoglu H, Ali A, Fordham E, LaMonica G (1996) Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 21(10):772-775
Brink I, Reinhardt MJ, Hoegerle S, Altehoefer C, Moser E, Nitzsche EU (2001) Increased metabolic activity in the thymus gland studied with 18F-FDG PET: age dependency and frequency after chemotherapy. J Nucl Med 42(4):591-595
Liu RS, Yeh SH, Huang MH, et al (1995) Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of thymoma: a preliminary report. Eur J Nucl Med 22(12):1402-1407
Tatlidil R, Jadvar H, Bading JR, Conti PS (2002) Incidental colonic fluorodeoxyglucose uptake: correlation with colonoscopic and histopathologic findings. Radiology 224(3):783-787
Delbeke D, Martin WH (2004) PET and PET-CT for evaluation of colorectal carcinoma. Semin Nucl Med 34(3):209-223
Denecke T, Rau B, Hoffmann KT, et al (2005) Comparison of CT, MRI and FDG- PET in response prediction of patients with locally advanced rectal cancer after multimodal preoperative therapy: is there a benefit in using functional imaging? Eur Radiol 15(8):1658-1666
Even-Sapir E, Parag Y, Lerman H, et al (2004) Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232(3):815-822
Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H (2005) Detection of residual tumor after radiofrequency ablation of liver metastasis with dual- modality PET/CT: initial results. Eur Radiol 16(1):80–87
Cohade C, Osman M, Leal J, Wahl RL (2003) Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44(11):1797-1803
Wahl RL (2004) Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med 45 Suppl 1:82S-95S
Chung JH, Cho KJ, Lee SS, et al (2004) Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging. J Nucl Med 45(6):999-1003
Tomita M, Ichinari H, Tomita Y, et al (2003) A case of non-small cell lung cancer with false-positive staging by positron emission tomography. Ann Thorac Cardiovasc Surg 9(6):397-400
Kamel EM, McKee TA, Calcagni ML, et al (2005) Occult lung infarction may induce false interpretation of (18)F-FDG PET in primary staging of pulmonary malignancies. Eur J Nucl Med Mol Imaging Feb 22
Shon IH, Fogelman I (2003) F-18 FDG positron emission tomography and benign fractures. Clin Nucl Med 28(3):171-175
von Schulthess GK, Meier N, Stumpe KD (2001) Joint accumulations of FDG in whole body PET scans. Nuklearmedizin 40(6):193-197
Dehdashti F, Siegel BA, Griffeth LK, et al (1996) Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18]fluoro-2- deoxy-D-glucose. Radiology 200(1):243-247
Shreve PD, Anzai Y, Wahl RL (1999) Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 19(1):61-77
Sugawara Y, Fisher SJ, Zasadny KR, Kison PV, Baker LH, Wahl RL (1998) Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. J Clin Oncol 16(1):173-180
Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF (2004) To enhance or not to enhance? 18F-FDG and CT contrast agents in dual- modality 18F-FDG PET/CT. J Nucl Med 45 Suppl 1:56S-65S
Antoch G, Freudenberg LS, Egelhof T, et al (2002) Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 43(10):1339-1342
Antoch G, Freudenberg LS, Stattaus J, et al (2002) Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 179(6):1555-1560
Beyer T, Antoch G, Muller S, et al (2004) Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 45 Suppl 1:25S-35S
Beyer T, Antoch G, Bockisch A, Stattaus J (2005) Optimized intravenous contrast administration for diagnostic whole-body 18F-FDG PET/CT. J Nucl Med 46(3):429-435
Kamel EM, Burger C, Buck A, von Schulthess GK, Goerres GW (2003) Impact of metallic dental implants on CT-based attenuation correction in a combined PET/CT scanner. Eur Radiol 13(4):724-728
Bockisch A, Beyer T, Antoch G, et al (2004) Positron emission tomography/computed tomography–imaging protocols, artifacts, and pitfalls. Mol Imaging Biol 6(4):188-199
Goerres GW, Kamel E, Heidelberg TN, Schwitter MR, Burger C, von Schulthess GK (2002) PET-CT image co-registration in the thorax: influence of respiration. Eur JNucl Med Mol Imaging 29(3):351-360
Osman MM, Cohade C, Nakamoto Y, Wahl RL (2003) Respiratory motion artifacts on PET emission images obtained using CT attenuation correction on PET-CT. Eur J Nucl Med Mol Imaging 30(4):603-606
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rosenbaum, S.J., Lind, T., Antoch, G. et al. False-Positive FDG PET Uptake−the Role of PET/CT. Eur Radiol 16, 1054–1065 (2006). https://doi.org/10.1007/s00330-005-0088-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00330-005-0088-y